Symbio-Labsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2012-01-20
Share capital
5 000,00 PLN
Activity description

Symbio-Lab provides contract manufacturing of food supplements and produces and sells private-label brands. Its formats include hard and soft capsules, regular and effervescent tablets, sachets and liquids; it also offers food filling and packaging.

Registered address
ul. Franciszka Żwirki I Stanisława Wigury 6C, 38-400 Krosno, Poland
Website
symbio-lab.comWebsite active
Email
Email address current
Phone
Social media
Electronic delivery address
AE:PL-27343-99774-ADWIB-29

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 920.36kMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 33.36kMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 873.06kMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 193.06kMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 2011-07-13. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Buildings and premises
PLN 333

Public aid

5 public aid cases recorded, with a total value of $19,314.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$3,852
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$1,577

European Funds

ProjectEU co-financing
Analiza prac B+R mających na celu uruchomienie produkcji linii suplementów diety z podkarpackich ziół wraz z analizą determinantów stosowania suplementów diety przez klientów na rynku polskim.
$11,025

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Grzegorz Boruta – President of the Management Board

Manner of representation

For performing legal acts, in the case of a multi-member management board, the joint action of two members of the management board is required.

Ownership

OwnerSharesShare valueStake
Adrian Maciej Boruta (29)
30$405.1930%
Grzegorz Boruta (59)
65$877.9065%
Others
5$67.535%

Grzegorz Boruta and Adrian Maciej Boruta hold a combined 95% – the ownership structure indicates family control.

Beneficial owners

Person

Competitors

Name
Labofarmsp. z o.o.
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.
Natur DayS.A.
Hauster sp. z o.o.sp. k.
PLON Pharmsp. z o.o.

Change history

DateEvent
2025-11-18Address change
2021-05-06PKD change
2015-03-27Name change
2015-03-27PKD change
2012-01-20Entered in the register

FAQ

Last updated: 2026-06-21